Novo Nordisk advances cardiometabolic pipeline with new data featuring CagriSema and zenagamtide at the American Diabetes Association's 2026 Scientific Sessions

Clinical 60/100Rated 60/100Source typeSpecialist communityIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
May 27, 2026↗ source

Novo Nordisk announced it will present data at the ADA 2026 Scientific Sessions on CagriSema (amylin analog plus GLP-1 RA), including Phase 3 REIMAGINE 1–3 results in type 2 diabetes, and Phase 2 data for the investigational once-weekly GLP-1/amylin injectable zenagamtide. Additional abstracts will cover semaglutide (Ozempic, Wegovy) and other pipeline candidates like IcoSema and efruxifermin. The company will host an investor webcast on the findings.

Related peptides

SemaglutideGLP-1 receptor agonistsGLP-1Amylinozempic - wegovyBINAZenagamtideGLP-1 RAGLP-1RsGLP-1IcoSema
We summarize, we don't invent — every detail here traces to a real, linked source, and the badge reflects how trustworthy that source is. Read the original and decide for yourself.

Free: The Peptide Stack Cheat-Sheet

The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.

No spam. Unsubscribe anytime.